Stocks · News reference
Whitehawk Therapeutics Presents Two-Real World Analyses Supporting Mucin 16
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Reported Sunday, Whitehawk's Real-World Data Show PTK7 Expression Remains Stable After Standard-Of-Care Therapies, Reinforcing Rationale For HWK-007 In EGFR Wild-Type NSCLC
PTK7 Expression Remained Stable Following Standard-of-Care Therapies, Supporting Its Relevance as a Target in Second- or Later-Line EGFR NSCLCFindings Reinforce the Scientific Rationale for HWK-007, Whitehawk's
8-K filing — Whitehawk Therapeutics, Inc. (WHWK)
Filed: 2026-09-10 AccNo: 0001193125-26-388010 Size: 168 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits